ストックスクリーナーアプリを入手
8.33
2.84%
0.23
アフターアワーズ：
8.34
0.010
+0.12%
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference - Yahoo Finance
Ocular Therapeutix at RBC Conference: Promising AXPAXLI Data By Investing.com - Investing.com Canada
OCUL: AXPAXLI showed phase III superiority over anti-VEGF, with strong regulatory and clinical momentum - TradingView
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Citizens reiterates Ocular Therapeutix stock rating amid litigation By Investing.com - Investing.com Canada
Jeffrey S. Heier, MD, Chief Scientific Officer, Ocular Therapeutix - Healio
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
EyePoint sues Ocular over claims related to lead asset - MSN
EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - GuruFocus
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha
EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart
On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget
EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks
Cantor Fitzgerald L. P. Buys Shares of 201,865 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (OCUL) Is Down 6.8% After VR Adviser Trims Stake Amid Margin Pressure - Sahm
VR Adviser Reduces Ocular Therapeutix Stake in Q4 2025 | Portfolio ImpactNews and Statistics - IndexBox
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down - AOL.com
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide - Yahoo Finance
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 20.0% in February - MarketBeat
Ocular Therapeutix Stock & Financial Performance Review 2026News and Statistics - IndexBox
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead - Yahoo Finance
A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Weakness - simplywall.st
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
201,865 Shares in Ocular Therapeutix, Inc. $OCUL Bought by Cantor Fitzgerald L. P. - MarketBeat
Is Ocular Therapeutix (OCUL) Pricing Reflect Its Volatile Returns And Rich Sales Multiple? - simplywall.st
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Purchased by Avoro Capital Advisors LLC - MarketBeat
Ocular Therapeutix Opens with 8.61% Gain Amid Ongoing Financial Challenges - Markets Mojo
Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug - TheStreet Pro
Rosalind Advisors Inc. Decreases Stock Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular Therapeutix at The Citizens Life Sciences Conference: AXPAXLI’s Promising Results - Investing.com Canada
OCUL: AXPAXLI's phase III success sets a new standard in wet AMD, with regulatory approval in progress - TradingView
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rhenman & Partners Asset Management AB Buys Shares of 202,000 Ocular Therapeutix, Inc. $OCUL - MarketBeat
Can Ocular Therapeutix Inc. stock surprise with earnings upsideJuly 2025 Intraday Action & Technical Buy Zone Confirmation - Naître et grandir
Ocular Therapeutix Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Ocular Therapeutix (OCUL) Is Up 16.2% After Detailing Retinal Pipeline Progress And Upcoming Milestones - Sahm
Ocular Therapeutix, Inc. $OCUL Shares Bought by Vanguard Group Inc. - MarketBeat
New Ocular Therapeutix Price Target as Stock Prepares to Blow Through the Old One - TheStreet Pro
Ocular Therapeutix, Inc. (OCUL) Competitors - Meyka
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler - The Globe and Mail
Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula SocietySlideshow - Seeking Alpha
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: 136% Potential Upside Captivates Investor Interest - DirectorsTalk Interviews
Ocular Therapeutix Stock Jumps 22.8% After Conference Update Ahead of Earnings - TIKR.com
1.82%
大文字化:
|
ボリューム (24 時間):